Cellular and Structural Biology | Faculty
Department of Cellular & Structural Biology

CSB Faculty

 

Photo of Dr. Freeman James W. Freeman, Ph.D.
Professor

 

University of Kentucky Medical Center, 1984

 

Department of Medicine/Division of Medical Oncology, UTHSCSA
Department of Cellular and Structural Biology, UTHSCSA
(210) 567-5298
freemanjw@uthscsa.edu

 

Dr. Freeman received his Ph.D. in Experimental Pathology from the University of Kentucky Medical Center in 1984 and did post-doctoral training in cancer biology at Baylor College of Medicine in Houston from 1984-1988. Dr. Freeman has served on numerous NIH/NCI and DOD study section panels. These include :NCI-Program Project Reviews, Experimental Therapeutics (2005-2006); K99/R00 Special Emphasis Panel (ZCA1 RTRB-A (2006); NCI-Tumor Microenvironment ZCA1 (2006); Program project cluster reviewer (NCI-D RPRB- 2004, 2005); SPORE reviewer; NCI ZCA1 SRRB-E - Head and Neck Cancer (2004); NCI Metabolic Pathology Study Section (2003-2004); NCI Cancer Epidemiology, Prevention and Control (2004-2005). He is a charter member of the Tumor Cell Biology Study Section on which he continues to serve. In 2005 he completed five years of service on the Manpower and Training Committee of the NCI. Dr. Freeman has been a faculty member at the University of Texas Health Science Center at San Antonio since 1998. He currently serves as the leader of the cell signaling group which is part of the experimental therapeutics program of he San Antonio Cancer Institute.

 

Dr. Freeman's research interest focus on the molecular biology and experimental therapeutics of pancreatic cancer. The overall goal of Dr. Freeman's laboratory is to make an impact on the treatment and management of pancreatic cancer by:

  1. determining the molecular mechanisms involved in aberrant cell signaling in the initiating stages of pancreatic cancer and those involved in the progression of pancreatic cancer;

  2. identifying methods for detection of early pancreatic cancer lesions and;

  3. evaluating the effectiveness of new agents that circumvent aberrant signaling for the purpose of prevention or therapy.
PUBLICATIONS:
Venkatasubbarao K, Choudary A, Freeman JW. (2005) Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.Cancer Res. Apr 1;65(7):2861-71.

 

Huang W, Zhao S, Ammanamanchi S, Brattain M, Venkatasubbarao K, Freeman JW. (2005) Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex.J Biol Chem. Mar 18;280(11):10047-54. Epub 2005 Jan 12.